As Microsoft, Intel, and Google lean into AI-driven restructuring, workers face shrinking salaries, fewer entry-level roles, ...

PATH has launched the largest study of its kind in Africa, recruiting 9,000 participants to test whether AI can help primary ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...

OpenEvidence, dubbed the 'ChatGPT for doctors,' uses AI to simplify evidence-based medical information for physicians, now ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Artificial intelligence startup OpenEvidence banked a $210 million series B round as it looks to expand its strategic content ...

Daniel Nadler started OpenEvidence to help physicians sort through a deluge of medical research. Now, he’s raised $210 ...

One of the biggest barriers to the adoption of any new biotechnology tool is validation and regulatory clarity.

Most U.S. adults find the information to be at least somewhat reliable, new research shows. But experts say there is ...

Traditionally, individuals asked health questions of their primary health care provider. Confidence in that provider as a ...

Traditionally, individuals asked health questions of their primary health care provider. Confidence in that provider as a ...